Free Trial
→ Only a handful of people know the setup that's defied these chaotic markets. (From WealthPress) (Ad) Buy SBTX Stock  Free SBTX Stock Alerts

Silverback Therapeutics (SBTX) Financials

Silverback Therapeutics logo
$14.98 +0.46 (+3.17%)
As of 05/23/2025
Compare
Annual Income Statements for Silverback Therapeutics

Annual Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 8.00 -54 -35 -20 -33
Consolidated Net Income / (Loss)		 8.00 -54 -35 -20 -33
Net Income / (Loss) Continuing Operations		 8.00 -54 -35 -20 -33
Total Pre-Tax Income 		8.29 -54 -35 -20 -33
Total Operating Income		 -3.08 -68 -36 -19 -33
Total Gross Profit		 88 0.03 1.32 5.51 0.00
Total Revenue		 89 0.03 1.32 5.51 0.00
Operating Revenue		 89 0.03 1.32 5.51 -
Total Cost of Revenue		 0.98 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 0.98 - - - -
Total Operating Expenses		 91 68 37 25 33
Selling, General & Admin Expense		 72 47 18 4.69 8.34
Research & Development Expense		 20 20 18 20 25
Total Other Income / (Expense), net		 11 13 0.83 -0.79 -0.03
Other Income / (Expense), net		 11 13 0.97 -0.79 -
Income Tax Expense		 0.29 0.00 - - -
Basic Earnings per Share		 $0.08 ($0.57) ($0.87) ($0.70) ($11.33)
Weighted Average Basic Shares Outstanding		 96.94M 95.22M 39.96M 28.87M 2.91M
Diluted Earnings per Share		 $0.08 ($0.57) ($0.87) ($0.70) ($11.33)
Weighted Average Diluted Shares Outstanding		 102.39M 95.22M 39.96M 28.87M 2.91M
Weighted Average Basic & Diluted Shares Outstanding		 98.12M 96.50M 94.40M 34.93M 2.91M

Quarterly Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 49 -19 -13 -10 -7.19 -15 -17 -15 -14 -6.58
Consolidated Net Income / (Loss)		 50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Net Income / (Loss) Continuing Operations		 50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Total Pre-Tax Income 		50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Total Operating Income		 47 -22 -15 -13 -10 -18 -21 -19 -15 -6.63
Total Gross Profit		 86 2.07 0.50 0.00 - 0.00 0.01 0.02 - 0.19
Total Revenue		 87 2.07 0.50 0.00 - 0.00 0.01 0.02 - 0.19
Operating Revenue		 87 2.07 0.50 0.00 - 0.00 0.01 0.02 - 0.19
Total Cost of Revenue		 0.98 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 38 24 16 13 10 18 21 19 15 6.82
Selling, General & Admin Expense		 35 19 8.94 7.96 6.82 15 13 12 11 2.93
Research & Development Expense		 3.03 4.42 6.90 5.23 3.40 3.00 7.31 6.55 4.71 3.89
Total Other Income / (Expense), net		 3.03 2.62 2.82 2.90 3.06 3.11 3.23 3.75 1.01 0.05
Other Income / (Expense), net		 3.03 2.62 2.82 2.90 3.06 3.11 3.23 3.75 1.15 0.05
Basic Earnings per Share		 $0.52 ($0.20) ($0.13) ($0.11) ($0.07) ($0.16) ($0.18) ($0.16) ($0.21) ($0.21)
Weighted Average Basic Shares Outstanding		 96.94M 97.03M 96.83M 96.49M 95.22M 95.58M 94.91M 94.23M 39.96M 30.76M
Diluted Earnings per Share		 $0.52 ($0.20) ($0.13) ($0.11) ($0.07) ($0.16) ($0.18) ($0.16) ($0.21) ($0.21)
Weighted Average Diluted Shares Outstanding		 102.39M 97.03M 96.83M 96.49M 95.22M 95.58M 94.91M 94.23M 39.96M 30.76M
Weighted Average Basic & Diluted Shares Outstanding		 98.12M 97.19M 96.94M 96.90M 96.50M 96.00M 95.57M 94.77M 94.40M 36.06M

Annual Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 -20 -140 150 36 376
Net Cash From Operating Activities		 14 -59 -40 -18 -31
Net Cash From Continuing Operating Activities		 14 -59 -40 -18 -31
Net Income / (Loss) Continuing Operations		 8.00 -54 -35 -20 -33
Consolidated Net Income / (Loss)		 8.00 -54 -35 -20 -33
Depreciation Expense		 0.08 0.07 0.03 0.21 0.64
Amortization Expense		 -7.25 -6.85 0.29 - 0.03
Non-Cash Adjustments To Reconcile Net Income		 15 9.24 7.04 2.83 3.71
Changes in Operating Assets and Liabilities, net		 -1.81 -7.36 -13 -0.36 -2.63
Net Cash From Investing Activities		 -106 -87 -0.20 -0.06 -0.92
Net Cash From Continuing Investing Activities		 -106 -87 -0.20 -0.06 -0.92
Purchase of Property, Plant & Equipment		 -0.56 -0.18 -0.20 -0.06 -0.92
Purchase of Investments		 -356 -272 0.00 0.00 0.00
Sale and/or Maturity of Investments		 258 185 0.00 - -
Other Investing Activities, net		 -7.50 0.00 - - -
Net Cash From Financing Activities		 72 6.90 191 53 409
Net Cash From Continuing Financing Activities		 72 6.90 191 53 409
Repayment of Debt		 0.00 0.00 -8.68 -1.82 -0.70
Issuance of Preferred Equity		 0.00 0.00 0.00 55 153
Issuance of Common Equity		 3.02 6.90 0.57 0.17 258
Other Financing Activities, net		 69 0.00 199 0.00 -2.61
Cash Interest Paid		 0.00 0.00 0.37 0.58 -

Quarterly Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 11 3.03 -19 -15 10 -58 31 -123 173 -7.27
Net Cash From Operating Activities		 42 -14 -7.28 -6.71 -17 -13 -17 -12 -20 -5.68
Net Cash From Continuing Operating Activities		 42 -14 -7.28 -6.71 -17 -13 -17 -12 -20 -5.68
Net Income / (Loss) Continuing Operations		 50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Consolidated Net Income / (Loss)		 50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Depreciation Expense		 0.03 0.02 0.02 0.01 0.01 0.02 0.02 0.02 0.01 0.01
Amortization Expense		 -1.54 -1.83 -1.90 -1.98 -1.73 -1.56 -1.75 -1.81 0.29 -
Non-Cash Adjustments To Reconcile Net Income		 4.23 3.59 3.37 3.35 2.28 2.61 2.10 2.25 5.84 0.50
Changes in Operating Assets and Liabilities, net		 -11 2.88 3.76 2.21 -11 1.03 0.33 2.07 -12 0.39
Net Cash From Investing Activities		 -102 17 -13 -8.51 26 -47 45 -112 -0.13 -0.03
Net Cash From Continuing Investing Activities		 -102 17 -13 -8.51 26 -47 45 -112 -0.13 -0.03
Purchase of Property, Plant & Equipment		 -0.30 -0.14 -0.04 -0.08 0.09 -0.04 -0.03 -0.19 -0.13 -0.03
Purchase of Investments		 -163 -42 -88 -63 -34 -107 - -131 - -
Sale and/or Maturity of Investments		 67 61 75 55 60 60 45 20 - -
Other Investing Activities, net		 -5.00 - - - - - - - - -
Net Cash From Financing Activities		 71 0.68 0.55 0.26 1.81 0.92 2.85 1.32 194 -1.56
Net Cash From Continuing Financing Activities		 71 0.68 0.55 0.26 1.81 0.92 2.85 1.32 194 -1.56
Issuance of Common Equity		 1.53 0.68 0.55 0.26 1.81 0.92 2.85 1.32 0.28 -

Annual Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 351 233 281 61 395
Total Current Assets		 334 232 278 61 391
Cash & Equivalents		 51 71 211 60 387
Short-Term Investments		 263 157 64 0.00 -
Accounts Receivable		 8.18 0.00 - 0.00 -
Inventories, net		 5.21 0.00 - - -
Prepaid Expenses		 6.89 3.37 3.32 0.67 4.09
Plant, Property, & Equipment, net		 1.03 0.57 0.33 0.07 1.62
Total Noncurrent Assets		 16 0.89 3.41 0.64 2.53
Intangible Assets		 7.37 0.00 - - -
Other Noncurrent Operating Assets		 8.46 0.89 3.41 0.64 2.53
Total Liabilities & Shareholders' Equity		 351 233 281 61 395
Total Liabilities		 94 2.43 8.55 17 12
Total Current Liabilities		 23 2.39 5.44 8.19 9.60
Accounts Payable		 23 2.15 4.93 3.11 2.58
Other Current Liabilities		 0.60 0.24 0.23 0.14 0.90
Total Noncurrent Liabilities		 71 0.04 3.11 8.49 2.33
Other Noncurrent Operating Liabilities		 71 0.04 0.25 0.56 2.33
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 257 231 273 -31 383
Total Preferred & Common Equity		 257 231 273 -31 383
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 257 231 273 -31 383
Common Stock		 380 362 349 11 480
Retained Earnings		 -123 -131 -77 -42 -97
Accumulated Other Comprehensive Income / (Loss)		 0.22 0.05 0.41 0.00 0.00

Quarterly Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 218 222 228 249 259 271 271
Total Current Assets		 209 221 226 244 255 267 271
Cash & Equivalents		 40 37 56 61 119 88 203
Short-Term Investments		 165 182 168 181 133 177 63
Accounts Receivable		 0.77 - - - - - -
Inventories, net		 0.72 - - - - - -
Prepaid Expenses		 2.68 1.99 2.61 2.56 2.83 2.80 4.18
Plant, Property, & Equipment, net		 0.84 0.64 0.62 0.62 0.59 0.58 0.02
Total Noncurrent Assets		 7.97 0.59 0.73 3.47 3.12 3.26 0.25
Long-Term Investments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible Assets		 7.50 - - - - - -
Other Noncurrent Operating Assets		 0.47 0.59 0.73 3.47 3.12 3.26 0.25
Total Liabilities & Shareholders' Equity		 218 222 228 249 259 271 271
Total Liabilities		 17 6.73 3.72 11 10 10 3.99
Total Current Liabilities		 17 6.73 3.72 11 10 9.84 3.99
Short-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable		 17 6.57 3.50 11 9.82 9.60 0.13
Accrued Expenses		 0.00 0.00 0.00 0.00 0.00 0.00 3.65
Current Deferred Revenue		 0.00 0.00 0.00 0.00 0.00 0.01 -
Other Current Liabilities		 0.10 0.16 0.22 0.24 0.23 0.23 0.22
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.09 0.15 0.20 0.00
Noncurrent Deferred Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 -
Other Noncurrent Operating Liabilities		 0.00 0.00 0.00 0.09 0.15 0.20 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 201 215 224 237 249 261 267
Total Preferred & Common Equity		 201 215 224 237 249 261 267
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 201 215 224 237 249 261 267
Common Stock		 374 369 366 362 358 353 517
Retained Earnings		 -173 -154 -142 -124 -109 -92 -248
Accumulated Other Comprehensive Income / (Loss)		 0.34 -0.15 -0.12 -0.16 -0.18 0.07 -1.62

Annual Metrics And Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 297,063.33% -97.72% -76.10% 0.00% 0.00%
EBITDA Growth		 101.82% -78.65% -70.86% 37.89% 0.00%
EBIT Growth		 115.24% -57.39% -70.64% 38.50% 0.00%
NOPAT Growth		 93.70% -90.11% -82.56% 40.90% 0.00%
Net Income Growth		 114.71% -56.75% -71.33% 38.56% 0.00%
EPS Growth		 114.04% 34.48% -24.29% 93.82% 0.00%
Operating Cash Flow Growth		 122.86% -47.88% -128.22% 43.71% 0.00%
Free Cash Flow Firm Growth		 210.73% -69.12% -215.70% 0.00% 0.00%
Invested Capital Growth		 -2,484.33% 260.54% 78.28% -141.71% 0.00%
Revenue Q/Q Growth		 3,371.53% 0.00% -80.71% 0.00% 0.00%
EBITDA Q/Q Growth		 101.97% 7.71% -230.69% 74.45% 0.00%
EBIT Q/Q Growth		 116.87% 11.58% -230.10% 74.43% 0.00%
NOPAT Q/Q Growth		 92.97% 7.17% -193.64% 75.43% 0.00%
Net Income Q/Q Growth		 116.29% 11.78% -235.89% 74.41% 0.00%
EPS Q/Q Growth		 115.69% 19.72% -264.15% -104.30% 0.00%
Operating Cash Flow Q/Q Growth		 129.54% 4.96% -582.11% 68.95% 0.00%
Free Cash Flow Firm Q/Q Growth		 230.75% -11.58% -271.53% 0.00% 0.00%
Invested Capital Q/Q Growth		 -1,469.50% 151.97% -432.22% 18.67% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 98.90% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 1.25% -203,800.00% -2,600.53% -363.79% 0.00%
Operating Margin		 -3.46% -225,066.67% -2,698.78% -353.32% 0.00%
EBIT Margin		 9.29% -181,216.67% -2,624.77% -367.65% 0.00%
Profit (Net Income) Margin		 8.97% -181,216.67% -2,635.41% -367.65% 0.00%
Tax Burden Percent		 96.52% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.41% 100.00% 100.09%
Effective Tax Rate		 3.48% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -10,445.08% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -10,442.26% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 10,423.49% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 3.28% -21.59% -21.84% -9.47% -8.61%
Cash Return on Invested Capital (CROIC)		 0.00% -2,131.63% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 2.84% -21.13% -20.15% -8.87% 0.00%
Return on Assets (ROA)		 2.74% -21.13% -20.23% -8.87% 0.00%
Return on Common Equity (ROCE)		 3.28% -21.59% -16.61% -7.78% -8.61%
Return on Equity Simple (ROE_SIMPLE)		 3.11% -23.56% -12.71% 64.74% -8.61%
Net Operating Profit after Tax (NOPAT)		 -2.98 -47 -25 -14 -23
NOPAT Margin		 -3.34% -157,546.67% -1,889.15% -247.33% 0.00%
Net Nonoperating Expense Percent (NNEP)		 4.05% -2.82% -6.02% -3.03% -2.57%
Return On Investment Capital (ROIC_SIMPLE)		 -1.16% -20.48% - - -
Cost of Revenue to Revenue		 1.10% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 80.40% 157,613.33% 1,402.43% 85.13% 0.00%
R&D to Revenue		 21.96% 67,553.33% 1,396.35% 368.20% 0.00%
Operating Expenses to Revenue		 102.36% 225,166.67% 2,798.78% 453.32% 0.00%
Earnings before Interest and Taxes (EBIT)		 8.29 -54 -35 -20 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.11 -61 -34 -20 -32
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 3.99 2.28 1.13 0.00 1.39
Price to Tangible Book Value (P/TBV)		 4.11 2.28 1.13 0.00 1.39
Price to Revenue (P/Rev)		 11.50 17,535.50 233.72 42.43 0.00
Price to Earnings (P/E)		 128.20 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.78% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 124.04 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.98 9,923.50 25.23 46.86 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 640.22 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 85.84 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 52.50 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.56 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.19 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.11 0.00
Financial Leverage		 -1.11 -1.00 -1.03 -1.02 -1.01
Leverage Ratio		 1.20 1.02 1.08 1.07 1.03
Compound Leverage Factor		 1.20 1.02 1.08 1.07 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 15.81% 0.22%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 6.54% 0.22%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 9.27% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 142.99% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% -58.80% 99.78%
Debt to EBITDA		 0.00 0.00 0.00 -0.42 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 2.58 11.96
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.25 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.62 -0.04
Net Debt to NOPAT		 0.00 0.00 0.00 3.79 16.74
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.36 0.00
Altman Z-Score		 7.42 129.62 21.96 7.47 27.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 23.94% 17.78% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 14.26 96.92 51.01 7.42 40.69
Quick Ratio		 13.75 95.51 50.40 7.34 40.26
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 57 -51 -30 -9.58 0.00
Operating Cash Flow to CapEx		 2,406.39% -33,866.29% -20,139.70% -31,929.09% -3,401.96%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -1,075.72
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,107.34
Efficiency Ratios		 - - - - -
Asset Turnover		 0.31 0.00 0.01 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 111.23 0.07 6.56 6.52 0.00
Accounts Payable Turnover		 0.08 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 4,668.97 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -4,668.97 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -57 2.40 -1.50 -6.88 -2.85
Invested Capital Turnover		 -3.25 0.07 -0.31 -1.13 0.00
Increase / (Decrease) in Invested Capital		 -60 3.90 5.39 -4.04 0.00
Enterprise Value (EV)		 711 298 33 258 147
Market Capitalization		 1,025 526 308 234 533
Book Value per Share		 $2.65 $2.40 $7.57 ($0.89) $131.68
Tangible Book Value per Share		 $2.57 $2.40 $7.57 ($0.89) $131.68
Total Capital		 257 231 273 53 384
Total Debt		 0.00 0.00 0.00 8.41 0.84
Total Long-Term Debt		 0.00 0.00 0.00 4.93 0.00
Net Debt		 -314 -228 -274 -52 -386
Capital Expenditures (CapEx)		 0.56 0.18 0.20 0.06 0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.17 0.98 -2.13 -4.04 -4.67
Debt-free Net Working Capital (DFNWC)		 311 229 272 56 382
Net Working Capital (NWC)		 311 229 272 53 381
Net Nonoperating Expense (NNE)		 -11 7.10 9.82 6.63 9.90
Net Nonoperating Obligations (NNO)		 -314 -228 -274 -52 -386
Total Depreciation and Amortization (D&A)		 -7.18 -6.78 0.32 0.21 0.67
Debt-free, Cash-free Net Working Capital to Revenue		 -3.55% 3,250.00% -161.47% -73.39% 0.00%
Debt-free Net Working Capital to Revenue		 348.69% 764,450.00% 20,688.15% 1,017.47% 0.00%
Net Working Capital to Revenue		 348.69% 764,450.00% 20,688.15% 954.29% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.08 ($0.57) ($0.87) ($2.56) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 96.94M 95.22M 39.96M 35.14M 0.00
Adjusted Diluted Earnings per Share		 $0.08 ($0.57) ($0.87) ($2.56) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 102.39M 95.22M 39.96M 35.14M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.56) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.12M 96.50M 94.40M 34.93M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -2.98 -47 -25 -14 -23
Normalized NOPAT Margin		 -3.34% -157,546.67% -1,889.15% -247.33% 0.00%
Pre Tax Income Margin		 9.29% -181,216.67% -2,635.41% -367.65% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -1,135.10
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -794.57
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,166.72
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -826.19
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 4,900.00% -100.00% 0.00% -100.00% -97.84% -96.98% 0.00% 0.00%
EBITDA Growth		 648.32% -27.60% 24.60% 26.80% 36.50% -149.47% -195.83% -132.64% -130.26% 70.74%
EBIT Growth		 800.64% -28.67% 27.94% 31.21% 49.84% -125.82% -170.56% -106.36% -130.65% 70.98%
NOPAT Growth		 759.34% -20.97% 25.54% 29.50% 33.78% -171.16% -224.76% -163.60% -123.19% 70.77%
Net Income Growth		 796.62% -28.67% 27.94% 31.21% 50.32% -125.82% -170.56% -106.36% -131.52% 70.94%
EPS Growth		 842.86% -25.00% 27.78% 31.25% 66.67% 23.81% 14.29% 33.33% -117.65% 67.69%
Operating Cash Flow Growth		 341.33% -13.35% 56.33% 46.01% 15.09% -124.62% -139.02% -79.48% -173.48% 70.28%
Free Cash Flow Firm Growth		 1,066.43% -115.46% 23.13% 10.01% 31.77% 44.55% -27.90% -158.02% -131.98% -82.86%
Invested Capital Growth		 -2,484.33% 21.05% 4.18% 106.95% 260.54% -1,126.22% -7.47% 26.06% 78.28% 105.32%
Revenue Q/Q Growth		 4,086.70% 313.60% 0.00% 0.00% 0.00% -100.00% -50.00% 0.00% 0.00% -59.27%
EBITDA Q/Q Growth		 332.68% -45.35% -17.46% -37.56% 45.85% 14.12% -14.04% -19.73% -112.74% -1.84%
EBIT Q/Q Growth		 362.56% -52.83% -21.61% -43.58% 51.78% 14.42% -16.10% -4.70% -117.06% -2.54%
NOPAT Q/Q Growth		 410.03% -41.77% -16.28% -29.00% 43.12% 12.74% -10.10% -21.17% -132.93% -4.51%
Net Income Q/Q Growth		 361.05% -52.83% -21.61% -43.58% 51.78% 14.42% -16.10% -3.69% -119.19% -2.54%
EPS Q/Q Growth		 360.00% -53.85% -18.18% -57.14% 56.25% 11.11% -12.50% 23.81% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 390.34% -98.75% -8.48% 61.45% -36.37% 23.43% -34.11% 39.36% -260.74% 18.53%
Free Cash Flow Firm Q/Q Growth		 759.57% -48.71% 15.34% -16.39% -47.05% 46.95% 0.89% 11.75% -19.51% -22.36%
Invested Capital Q/Q Growth		 -1,469.50% -4.08% -1,584.32% -90.17% 151.97% -26.31% -7.72% -127.02% -432.22% 113.23%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 98.87% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 56.26% -1,012.23% -2,880.40% 0.00% 0.00% 0.00% -191,020.00% -83,750.00% 0.00% -3,479.37%
Operating Margin		 54.51% -1,051.64% -3,068.00% 0.00% 0.00% 0.00% -206,030.00% -93,565.00% 0.00% -3,507.94%
EBIT Margin		 58.01% -924.95% -2,503.20% 0.00% 0.00% 0.00% -173,700.00% -74,805.00% 0.00% -3,483.07%
Profit (Net Income) Margin		 57.67% -924.95% -2,503.20% 0.00% 0.00% 0.00% -173,700.00% -74,805.00% 0.00% -3,483.07%
Tax Burden Percent		 99.43% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.98% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 3.28% -22.41% -19.34% -20.49% 0.00% -24.44% -20.23% -15.29% -21.84% 8.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -19,927.67% -2,131.63% 0.00% 0.00% 0.00% 0.00% 3,919.11%
Operating Return on Assets (OROA)		 17.70% -10.19% -5.21% 0.00% 0.00% 0.00% -137.64% -172.51% 0.00% -76.20%
Return on Assets (ROA)		 17.60% -10.19% -5.21% 0.00% 0.00% 0.00% -137.64% -172.51% 0.00% -76.20%
Return on Common Equity (ROCE)		 3.28% -22.41% -19.34% -20.49% 0.00% -24.44% -20.23% -15.29% -16.61% 8.52%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -24.43% -20.83% -22.20% 0.00% -25.97% -21.46% -16.23% 0.00% 9.56%
Net Operating Profit after Tax (NOPAT)		 47 -15 -11 -9.23 -7.16 -13 -14 -13 -11 -4.64
NOPAT Margin		 54.51% -736.15% -2,147.60% 0.00% 0.00% 0.00% -144,221.00% -65,495.50% 0.00% -2,455.56%
Net Nonoperating Expense Percent (NNEP)		 1.01% -1.75% -0.76% -0.43% 0.00% -0.90% -1.10% -0.66% -2.22% -0.64%
Return On Investment Capital (ROIC_SIMPLE)		 18.38% - - - -3.10% - - - - -
Cost of Revenue to Revenue		 1.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 40.99% 932.35% 1,788.80% 0.00% 0.00% 0.00% 133,050.00% 60,905.00% 0.00% 1,548.15%
R&D to Revenue		 3.50% 213.88% 1,379.20% 0.00% 0.00% 0.00% 73,080.00% 32,760.00% 0.00% 2,059.79%
Operating Expenses to Revenue		 44.36% 1,151.64% 3,168.00% 0.00% 0.00% 0.00% 206,130.00% 93,665.00% 0.00% 3,607.94%
Earnings before Interest and Taxes (EBIT)		 50 -19 -13 -10 -7.17 -15 -17 -15 -14 -6.58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 49 -21 -14 -12 -8.88 -16 -19 -17 -14 -6.58
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.99 6.99 3.83 4.41 2.28 1.52 2.55 2.35 1.13 0.70
Price to Tangible Book Value (P/TBV)		 4.11 7.27 3.83 4.41 2.28 1.52 2.55 2.35 1.13 0.70
Price to Revenue (P/Rev)		 11.50 547.37 1,649.16 98,624.59 17,535.50 12,041.61 2,899.49 913.17 233.72 27.46
Price to Earnings (P/E)		 128.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.22
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.71%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 3,231.41 124.04 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 7.98 467.69 1,211.67 76,261.39 9,923.50 3,978.21 1,747.85 520.08 25.23 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 640.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 85.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 52.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.11 -1.02 -1.02 -1.01 -1.00 -1.01 -1.01 -1.01 -1.03 -1.01
Leverage Ratio		 1.20 1.06 1.04 1.03 1.02 1.03 1.05 1.05 1.08 1.04
Compound Leverage Factor		 1.20 1.06 1.04 1.03 1.02 1.03 1.05 1.05 1.09 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.82 50.40 73.57 159.44 130.29 19.46 37.68 37.22 22.20 28.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.94% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 14.26 12.56 32.82 60.90 96.92 21.87 25.37 27.18 51.01 67.87
Quick Ratio		 13.75 12.36 32.53 60.20 95.51 21.64 25.09 26.89 50.40 66.82
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 107 -16 -11 -13 -11 -7.52 -14 -14 -16 -14
Operating Cash Flow to CapEx		 13,908.61% -10,333.57% -19,155.26% -8,084.34% 0.00% -29,681.40% -55,563.33% -6,439.90% -16,267.46% -18,940.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.31 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 111.23 3.52 0.81 0.02 0.07 0.09 0.14 0.45 6.56 7.10
Accounts Payable Turnover		 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 4,668.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -4,668.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -57 -3.65 -3.50 0.24 2.40 -4.62 -3.66 -3.39 -1.50 0.45
Invested Capital Turnover		 -3.25 -0.62 -0.14 -0.01 0.07 -0.01 -0.06 -0.17 -0.31 -1.70
Increase / (Decrease) in Invested Capital		 -60 0.97 0.15 3.63 3.90 -5.07 -0.25 1.20 5.39 8.91
Enterprise Value (EV)		 711 1,201 606 763 298 119 383 350 33 -79
Market Capitalization		 1,025 1,406 825 986 526 361 635 615 308 187
Book Value per Share		 $2.65 $2.07 $2.22 $2.32 $2.40 $2.48 $2.62 $2.77 $7.57 $7.53
Tangible Book Value per Share		 $2.57 $2.00 $2.22 $2.32 $2.40 $2.48 $2.62 $2.77 $7.57 $7.53
Total Capital		 257 201 215 224 231 237 249 261 273 267
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -314 -205 -219 -224 -228 -242 -252 -265 -274 -267
Capital Expenditures (CapEx)		 0.30 0.14 0.04 0.08 -0.09 0.04 0.03 0.19 0.13 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.17 -12 -4.73 -1.11 0.98 -8.62 -7.23 -7.04 -2.13 0.19
Debt-free Net Working Capital (DFNWC)		 311 192 214 223 229 233 245 258 272 267
Net Working Capital (NWC)		 311 192 214 223 229 233 245 258 272 267
Net Nonoperating Expense (NNE)		 -2.74 3.90 1.78 1.06 0.01 2.28 2.95 1.86 3.62 1.94
Net Nonoperating Obligations (NNO)		 -314 -205 -219 -224 -228 -242 -252 -265 -274 -267
Total Depreciation and Amortization (D&A)		 -1.52 -1.81 -1.89 -1.97 -1.72 -1.54 -1.73 -1.79 0.30 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -3.55% -485.12% -946.20% -11,060.00% 3,250.00% -28,720.00% -3,300.46% -1,045.62% -161.47% 2.71%
Debt-free Net Working Capital to Revenue		 348.69% 7,483.10% 42,802.60% 2,225,260.00% 764,450.00% 777,620.00% 111,863.01% 38,263.30% 20,688.15% 3,911.01%
Net Working Capital to Revenue		 348.69% 7,483.10% 42,802.60% 2,225,260.00% 764,450.00% 777,620.00% 111,863.01% 38,263.30% 20,688.15% 3,911.01%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.52 ($0.20) ($0.13) ($0.11) ($0.07) ($0.16) ($0.18) ($0.16) ($0.21) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding		 96.94M 97.03M 96.83M 96.49M 95.22M 95.58M 94.91M 94.23M 39.96M 35.46M
Adjusted Diluted Earnings per Share		 $0.52 ($0.20) ($0.13) ($0.11) ($0.07) ($0.16) ($0.18) ($0.16) ($0.21) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding		 102.39M 97.03M 96.83M 96.49M 95.22M 95.58M 94.91M 94.23M 39.96M 35.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.12M 97.19M 96.94M 96.90M 96.50M 96.00M 95.57M 94.77M 94.40M 36.06M
Normalized Net Operating Profit after Tax (NOPAT)		 33 -15 -11 -9.23 -7.16 -13 -14 -13 -11 -4.64
Normalized NOPAT Margin		 38.16% -736.15% -2,147.60% 0.00% 0.00% 0.00% -144,221.00% -65,495.50% 0.00% -2,455.56%
Pre Tax Income Margin		 58.01% -924.95% -2,503.20% 0.00% 0.00% 0.00% -173,700.00% -74,805.00% 0.00% -3,483.07%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Silverback Therapeutics' Financials

When does Silverback Therapeutics's financial year end?

According to the most recent income statement we have on file, Silverback Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Silverback Therapeutics' net income changed over the last 4 years?

Silverback Therapeutics' net income appears to be on a downward trend, with a most recent value of $8.00 million in 2024, falling from -$32.95 million in 2020. The previous period was -$54.37 million in 2023.

What is Silverback Therapeutics's operating income?
Silverback Therapeutics's total operating income in 2024 was -$3.08 million, based on the following breakdown:
  • Total Gross Profit: $88.17 million
  • Total Operating Expenses: $91.26 million
How has Silverback Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Silverback Therapeutics' total revenue changed from $0.00 in 2020 to $89.15 million in 2024, a change of 8,914,900,000.0%.

How much debt does Silverback Therapeutics have?

Silverback Therapeutics' total liabilities were at $94.36 million at the end of 2024, a 3,786.1% increase from 2023, and a 691.1% increase since 2020.

How much cash does Silverback Therapeutics have?

In the past 4 years, Silverback Therapeutics' cash and equivalents has ranged from $50.82 million in 2024 to $386.57 million in 2020, and is currently $50.82 million as of their latest financial filing in 2024.

How has Silverback Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Silverback Therapeutics' book value per share changed from 131.68 in 2020 to 2.65 in 2024, a change of -98.0%.


Related Companies

This page (NASDAQ:SBTX) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored